Abstract: The present invention relates to novel protein pores and their uses in analyte detection and characterisation. The invention particularly relates to an isolated pore complex formed by a CsgG-like pore and a modified CsgF peptide, or a homologue or mutant thereof, thereby incorporating an additional channel constriction or reader head in the nanopore. The invention further relates to a transmembrane pore complex and methods for production of the pore complex and for use in molecular sensing and nucleic acid sequencing applications.

Abstract: A respiratory interface system for use in delivering a flow of a positive pressure breathing gas to an airway of a patient that includes a patient interface device with a tubing assembly structured to be disposed on the head of the patient, a mask having a sealing element structured to sealingly engage about the airway of the patient, and an adaptor. The adapter includes a flange portion that extends generally radially outward from a central aperture and a hollow male connector extending from the flange portion and coupled with a correspondingly-shaped female connector of the tubing assembly or the mask. The mask is coupled to the tubing assembly via the adaptor, and the tubing assembly, the mask, and the adapter define a pathway structured to conduct the flow of the positive pressure breathing gas to the airway of the patient.

Abstract: An example system includes a vehicle having a prime mover motively coupled to a drive line; a motor/generator selectively coupled to the drive line, and configured to selectively modulate power transfer between an electrical load and the drive line; a battery pack; a DC/DC converter electrically interposed between the motor/generator and the electrical load, and between the battery pack and the electrical load, the DC/DC converter comprising a DC/DC converter housing; and a covering tray positioned over a plurality of batteries of the battery pack, the covering tray comprising a connectivity layer configured to provide electrical connectivity to terminals of the plurality of batteries.

Abstract: A method for generating an adaptive user interface may include, generating a graphical user interface for presentation to a user at an automated banking machine that includes a touch screen display and a currency note dispenser. The automated banking machine may include a sensor that senses information indicating a physical disposition of the user relative to the automated banking machine. The method may include adjusting the placement of the menu options on the touch screen display based on the information regarding the physical disposition of the user relative to the automated banking machine.

Abstract: The present disclosure relates to methods of treating EPAS1-related diseases such as cancer, metastases, astrocytoma, bladder cancer, breast cancer, chondrosarcoma, colorectal carcinoma, gastric carcinoma, glioblastoma, head and neck squamous cell carcinoma, hepatocellular carcinoma, lung adenocarcinoma, neuroblastoma, non-small cell lung cancer, melanoma, multiple myeloma, ovarian cancer, rectal cancer, renal cancer, clear cell renal cell carcinoma (and metastases of this and other cancers), gingivitis, psoriasis, Kaposi's sarcoma-associated herpesvirus, preeclampsia, inflammation, chronic inflammation, neovascular diseases, and rheumatoid arthritis, using a therapeutically effective amount of a RNAi agent to EPAS1.

Abstract: The present invention relates to methods for the screening, identification and/or application of microorganisms and/or compositions of use in imparting beneficial properties to plants, and microorganisms and compositions identified therefrom.

Abstract: The present invention relates to methods for the screening, identification and/or application of microorganisms and/or compositions of use in imparting beneficial properties to plants, and microorganisms and compositions identified therefrom.

Abstract: The present disclosure relates to methods of treating EPAS1-related diseases such as cancer, metastases, astrocytoma, bladder cancer, breast cancer, chondrosarcoma, colorectal carcinoma, gastric carcinoma, glioblastoma, head and neck squamous cell carcinoma, hepatocellular carcinoma, lung adenocarcinoma, neuroblastoma, non-small cell lung cancer, melanoma, multiple myeloma, ovarian cancer, rectal cancer, renal cancer, clear cell renal cell carcinoma (and metastases of this and other cancers), gingivitis, psoriasis, Kaposi's sarcoma-associated herpesvirus, preemclampsia, inflammation, chronic inflammation, neovascular diseases, and rheumatoid arthritis, using a therapeutically effective amount of a RNAi agent to EPAS1.

Abstract: The present disclosure relates to methods of treating EPAS1-related diseases such as cancer, metastases, astrocytoma, bladder cancer, breast cancer, chondrosarcoma, colorectal carcinoma, gastric carcinoma, glioblastoma, head and neck squamous cell carcinoma, hepatocellular carcinoma, lung adenocarcinoma, neuroblastoma, non-small cell lung cancer, melanoma, multiple myeloma, ovarian cancer, rectal cancer, renal cancer, clear cell renal cell carcinoma (and metastases of this and other cancers), gingivitis, psoriasis, Kaposi's sarcoma-associated herpesvirus, preemclampsia, inflammation, chronic imflammation, neovascular diseases, and rheumatoid arthritis, using a therapeutically effective amount of a RNAi agent to EPAS1.

Abstract: The present disclosure relates to methods of treating EPAS1-related diseases such as cancer, metastases, astrocytoma, bladder cancer, breast cancer, chondrosarcoma, colorectal carcinoma, gastric carcinoma, glioblastoma, head and neck squamous cell carcinoma, hepatocellular carcinoma, lung adenocarcinoma, neuroblastoma, non-small cell lung cancer, melanoma, multiple myeloma, ovarian cancer, rectal cancer, renal cancer, clear cell renal cell carcinoma (and metastases of this and other cancers), gingivitis, rheumatoid arthritis, using a therapeutically effective amount of a RNAi agent to EPAS1.

Abstract: The present invention relates to methods for the screening, identification and/or application of microorganisms and/or compositions of use in imparting beneficial properties to plants, and microorganisms and compositions identified therefrom.

Abstract: The present disclosure relates to methods of treating EPAS1-related diseases such as cancer, metastases, astrocytoma, bladder cancer, breast cancer, chondrosarcoma, colorectal carcinoma, gastric carcinoma, glioblastoma, head and neck squamous cell carcinoma, hepatocellular carcinoma, lung adenocarcinoma, neuroblastoma, non-small cell lung cancer, melanoma, multiple myeloma, ovarian cancer, rectal cancer, renal cancer, clear cell renal cell carcinoma (and metastases of this and other cancers), gingivitis, psoriasis, Kaposi's sarcoma-associated herpesvirus, preemclampsia, inflammation, chronic inflammation, neovascular diseases, and rheumatoid arthritis, using a therapeutically effective amount of a RNAi agent to EPAS1.

Abstract: The present invention relates to methods for the screening, identification and/or application of microorganisms and/or compositions of use in imparting beneficial properties to plants, and microorganisms and compositions identified therefrom.

Abstract: The present disclosure relates to methods of treating EPAS1-related diseases such as cancer, metastases, astrocytoma, bladder cancer, breast cancer, chondrosarcoma, colorectal carcinoma, gastric carcinoma, glioblastoma, head and neck squamous cell carcinoma, hepatocellular carcinoma, lung adenocarcinoma, neuroblastoma, non-small cell lung cancer, melanoma, multiple myeloma, ovarian cancer, rectal cancer, renal cancer, clear cell renal cell carcinoma (and metastases of this and other cancers), gingivitis, psoriasis, Kaposi's sarcoma-associated herpesvirus, preemclampsia, inflammation, chronic inflammation, neovascular diseases, and rheumatoid arthritis, using a therapeutically effective amount of a RNAi agent to EPAS1.

Abstract: The present invention relates to methods for the screening, identification and/or application of microorganisms and/or compositions of use in imparting beneficial properties to plants, and microorganisms and compositions identified therefrom.

Abstract: The present invention relates to methods for the screening, identification and/or application of microorganisms and/or compositions of use in imparting beneficial properties to plants, and microorganisms and compositions identified therefrom.

Abstract: A method and apparatus for increasing the number of storage units. Specifically, the present invention describes a method for creating a plurality of virtual logical units (LUN) of storage from a plurality of existing volumes of storage for access by a plurality of host applications via a virtualization layer. The virtual LUNs are created by partitioning the existing volumes into a plurality of slices. Each of the plurality of slices is then mapped to the plurality of virtual LUNs. Furthermore, each of the plurality of virtual LUNs is masked to each of the plurality of host applications to provide access control. The plurality of host applications are transparently interfaced to the existing volume while preserving the original configuration of internal operating code or intelligence for interfacing with the plurality of existing volumes.

Abstract: A method and apparatus for increasing the number of storage units. Specifically, the present invention describes a method for creating a plurality of virtual logical units (LUN) of storage from a plurality of existing volumes of storage for access by a plurality of host applications via a virtualization layer. The virtual LUNs are created by partitioning the existing volumes into a plurality of slices. Each of the plurality of slices is then mapped to the plurality of virtual LUNs. Furthermore, each of the plurality of virtual LUNs is masked to each of the plurality of host applications to provide access control. The plurality of host applications are transparently interfaced to the existing volume while preserving the original configuration of internal operating code or intelligence for interfacing with the plurality of existing volumes.

Abstract: A method and an apparatus for a dynamic error injection mechanism used in conjunction with a behavioral simulator in testing simulated hardware and software, and more particularly the testing of error handling code. In one implementation of the invention, Sun Microsystem's MPSAS (MULTI-PROCESSOR SPARC ARCHITECTURAL SIMULATOR) may be utilized as a behavioral model to implement the present invention. With the present invention, a range of addresses may be specified within which to test such errors. When such a command is issued, MPSAS logs the error and address range. Simulation can then be continued. At the next access to the address range to be tested with for a specific error, the present invention triggers off simulated hardware actions which would be taken in an actual hardware upon its encountering the same error. If the corresponding error handlers are turned on by the software of the present invention, the trap will be taken and the code will vector off to the error handler.